HIGHLY ACTIVE, LONG-ACTING ANTI-DIABETIC FUSION PROTEIN, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF

Title:

HIGHLY ACTIVE, LONG-ACTING ANTI-DIABETIC FUSION PROTEIN, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF

Document Type and Number:

WIPO Patent Application WO/2018/032929

Kind Code:

A1

Abstract:

Provided is a highly active, long-acting anti-diabetic fusion protein. The protein is formed by connecting, directly or via a linker peptide, a highly active exenatide mutant to an optimally mutated Fc1 fragment of a human immunoglobulin IgG1. The optimally mutated Fc1 fragment of the human immunoglobulin IgG1 comprises: an optimally mutated human IgG1 hinge region and human IgG1 constant regions CH2 and CH3.

More Like This:

JP2003530107	[Title of Invention] Identification of a New Human GABA Transporter
WO/2000/063395	NUCLEIC ACIDS ENCODING CD40/CD40L CHIMERIC POLYPEPTIDES, METHODS FOR THEIR PRODUCTION AND USES THEREOF
WO/2013/078425	LAMBODIES WITH HIGH AFFINITY AND SELECTIVITY FOR GLYCANS AND USES THEREFOR

Inventors:

TAN SHUHUA (CN)
GU LILI (CN)
FU JIAN (CN)
ZHANG YONGBO (CN)
TIAN QINGHUA (CN)
WANG YUE (CN)
GONG XIAOJIAN (CN)

Application Number:

PCT/CN2017/093699

Publication Date:

February 22, 2018

Filing Date:

July 20, 2017

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV CHINA PHARMA (CN)

International Classes:

C07K19/00; A61K38/22; C12N15/62

Domestic Patent References:

WO2011153965A1

2011-12-15

Foreign References:

CN106046176A	2016-10-26
CN102558362A	2012-07-11
CN105753963A	2016-07-13
US20050186662A1	2005-08-25
CN1483041A	2004-03-17
CN102311501A	2012-01-11
CN102453094A	2012-05-16
CN102952192A	2013-03-06

Attorney, Agent or Firm:

NANJING IPLEADER INTELLECTUAL PROPERTY AGENCY FIRM (SPECIAL GENERAL PARTNER) (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: SHIFT REGISTER UNIT, DRIVING METHOD, AND GATE DRIVING CIRCUIT

Next Patent: METHOD AND DEVICE FOR VOICE INTERACTION CONTROL OF SMART DEVICE